NCT06810050 - Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

October 30, 2025

Conditions

Atopic Dermatitis (AD)

Interventions

DRUG

CGB-500 with 0.5% tofacitinib

CGB-500 is a proprietary ointment formulation

DRUG

CGB-500 Ointment with 1% tofacitinib

CGB-500 is a proprietary ointment formulation

DRUG

Vehicle (placebo)

placebo ointment

Trial Locations (16)

33027

RECRUITING

FXM Clinical Research Miramar, LLC, Miramar

33126

RECRUITING

USA and International Research Inc., Doral

33134

RECRUITING

Driven Research, Gables

33175

RECRUITING

FXM Clinical Research Miami, LLC, Miami

33182

RECRUITING

Cordova Research Institute, Sweetwater

33308

RECRUITING

FXM Clinical Research, Fort Lauderdale

37215

RECRUITING

Tennessee Clinical Research Center, Nashville

46168

RECRUITING

The Indiana Clinical Trials Center, PC, Plainfield

55112

RECRUITING

J&S Studies, Inc., New Brighton

78759

RECRUITING

DermResearch, Austin

89148

RECRUITING

JDR Dermatology Research, Las Vegas

90266

RECRUITING

Ablon Skin Institute and Research Center, Manhattan Beach

92123

RECRUITING

TCR Medical Corporation, San Diego

92705

RECRUITING

Syrentis Clinical Research, Santa Ana

94538

RECRUITING

Center for Dermatology Clinical Research Inc., Fremont

02135

RECRUITING

Metro Boston Clinical Partners, Brighton